Theemmesgroup
theemmesgroup.com
Cell & Gene Therapy
Biotechnology
Health Care
Claim pageClaim
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Behrman Capital
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 2026
Formerly Emmes (emmes.com)
1981
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Behrman Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Discover GC Therapeutics, a pioneer in scalable, cutting-edge cell therapies designed to revolutionize treatment across a broad range of…
Next-generation CAR T-cell therapies engineered to disrupt the tumor microenvironment OUR MISSION CARTemis Therapeutics is a clinical-stage…
At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.
T cell Based Immunotherapies for Cancer and Chronic Infectious Diseases.
Our therapeutic areas. LifeHealthcare, through our organic growth, and the addition of new organisations is continuing to grow our…
Cellcolabs produces GMP mesenchymal stem cells (MSCs) for clinical research and collaboration with clinics and scientists worldwide.
Overview
For over 40 years, our team of 1,000+ experienced professionals have provided the full range of Contract Research Organization expertise necessary to conduct clinical research with a firm scientific basis that is fully compliant with national and international regulatory guidelines. With offices throughout the US, Europe, Canada, and India, Emmes supports the advancement of global public health and biopharmaceutical innovation through disciplined science, rigorous research, fact-based decision-making, and operational excellence. Emmes possesses knowledge across a broad range of therapeutic areas, with specializations in Vaccines and Infectious Diseases, Ophthalmology, Immunology and Neuroscience.